At present, Venetoclax, the first highly selective BCL-2 inhibitor, has been approved by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [2]. Here, BCL2 is linked to acute myeloid leukemia.